

IMPACT OF INTOLERANCE ON PATIENT GOALS

Susan enjoys volunteering and spending time with her family. While achieving a solid response from her CML treatment, she deals with ongoing AEs that disrupt her daily life.

Sokal risk score	Low risk (0.7)
Current treatment	2nd-line TKI
Length of time on current treatment	12 months
Molecular status	1% BCR-ABL1
Persistent AEs	Diarrhea, nausea

- Susan has noted that her persistent AEs have become intolerable. How would her patient goals influence your clinical assessment?
- According to National Comprehensive Cancer Network® (NCCN®), patients with >0.1% to 1% BCR-ABL1 at 12 months have TKI-sensitive disease, and patient goals may influence clinical considerations

LEARN ABOUT UNMET NEEDS IN CML. [VISIT OUR SITE](#)

TARGETCML

AEs, adverse events; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March, 20, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2021 Novartis

3/21

111558

